Caribou Biosciences Inc. (NASDAQ:CRBU) finished Wednesday with an addition of $0.38 to close at $6.92, an upside of 5.81 percent. An average of 1,356,460 shares of common stock have been traded in the last five days. There was a fall of -$0.14 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 2,570,655 shares traded, while the 50-day average volume stands at 3,748,068.
CRBU stock has decreased by -10.01% in the last month. The company shares reached their 1-month lowest point of $6.08 on 07/17/23. With the stock rallying to its 52-week high on 07/12/23, shares of the company touched a low of $3.96 and a high of $13.19 in 52 weeks. It has reached a new high 8 times so far this year and achieved 10.19% or $0.64 in price. In spite of this, the price is down -47.54% from the 52-week high.
Insider Transactions
CRBU stock investors should be aware that Caribou Biosciences Inc. (CRBU) stock had its last reported insider trading activity 203 days ago on Jan 19. In this transaction, the insider spent $35,506. VP of Finance and Controller, Fischesser Ryan, disposed of 10,000 shares at a price of $10.80 on Oct 06. The insider now owns more than $107,958 worth of shares. Prior to that, Chief Scientific Officer Kanner Steven went on to Sale 43,248 shares at $11.22 each on Aug 25. An amount of $485,221 was transacted.
Valuation Metrics
Caribou Biosciences Inc. (CRBU) stock’s beta is 1.95. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 39.98, the price-to-book (PB) ratio at 1.52.
Financial Health
The quick ratio of Caribou Biosciences Inc. for the three months ended June 29 was 8.80, and the current ratio was 8.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Caribou Biosciences Inc.’s EBITDA margin for the year ending June 29 is -741.88%. Its gross profit as reported stood at $120.25 million compared to revenue of $13.85 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Caribou Biosciences Inc.’s return on assets was -28.10%.
Earnings Surprise
For the three-month period that ended June 29, Caribou Biosciences Inc. had $193.04 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$29.52 million in the quarter, while revenues were grew 9.55%. The analyst consensus anticipated Caribou Biosciences Inc.’s latest quarter earnings to come in at -$0.49 per share, but it turned out to be -$0.48, a 2.00% surprise. For the quarter, EBITDA amounted to -$34.35 million. At the end of the quarter ending June 29, Caribou Biosciences Inc.’s stock balance sheet showed total liabilities of 80.19 million. Shareholders own equity worth $88.28 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Caribou Biosciences Inc. (CRBU) price momentum. RSI 9-day as of the close on 09 August was 56.27%, suggesting the stock is Neutral, with historical volatility in this time frame at 59.93%.
As of today, CRBU’s price is $6.72 -1.98% or -$0.14 from its 5-day moving average. CRBU is currently trading -10.82% lower than its 20-day SMA and +37.30% higher than its 100-day SMA. However, the stock’s current price level is +57.09% above the SMA50 and -23.03% below the SMA200.
The stochastic %K and %D were 30.33% and 30.70%, respectively, and the average true range (ATR) was 0.51. With the 14-day stochastic at 50.00% and the average true range at 0.53, the RSI (14) stands at 56.98%. The stock has reached -0.21 on the 9-day MACD Oscillator while the 14-day reading was at -0.10.
Analyst Ratings
Truist launched coverage on Caribou Biosciences Inc. (NASDAQ: CRBU) in its analyst report released on July 11, 2023. The firm assigned the stock a Buy rating. The consensus rating for Caribou Biosciences Inc. (CRBU) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CRBU, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is CRBU’s price target for the next 12 months?
Analysts predict a range of price targets between $19.00 and $37.00, with a median target of $23.00. Taking a look at these predictions, the average price target given by analysts for Caribou Biosciences Inc. (CRBU) stock is $24.86.
